Welcome to LookChem.com Sign In|Join Free

CAS

  • or

115027-25-3

Post Buying Request

115027-25-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

115027-25-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 115027-25-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,0,2 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 115027-25:
(8*1)+(7*1)+(6*5)+(5*0)+(4*2)+(3*7)+(2*2)+(1*5)=83
83 % 10 = 3
So 115027-25-3 is a valid CAS Registry Number.

115027-25-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(2-chloroacetyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:115027-25-3 SDS

115027-25-3Upstream product

115027-25-3Relevant articles and documents

2-guanidino-4-arylthiazoles for treatment of peptic ulcers

-

, (2008/06/13)

2-Guanidino-4-arylthiazole compounds of the formula STR1 a pharmaceutically acceptable cationic or acid addition salt thereof wherein R1 is hydrogen, (C1 -C10)alkyl, optionally substituted phenyl or certain optionally substituted aralkyl groups; R2 is hydrogen or (C1 -C4)alkyl, and Ar is certain optionally substituted pyrrolyl or indolyl groups; method for their use in treatment of gastric ulcers, by inhibition of parietal cell H+ /K+ ATPase, and antiinflammatory conditions in combination with piroxicam, for use in mammals, and pharmaceutical compositions containing said compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 115027-25-3